Articles by Chirag Shah, MD
48 Validation of a Multi-omic Biosignature to Predict Locoregional Recurrence Risk and the Benefit of Adjuvant Radiation Therapy in Women With Early-Stage Invasive Breast Cancer Treated With Breast-Conserving Surgery and Endocrine Therapy
ByG. Bruce Mann,Karuna Mittal,Richard De Boer,Caroline MacCallum,Michael D. Alvarado,Michael Christie,Frank Vicini, MD,Chirag Shah, MD,Y. V. Zou,Mark Mentrikoski,Jess Savala,David J. Dabbs,Steven C. Shivers,Pat W. Whitworth,Troy Bremer In an external blinded validation of 426 women with HR-positive, HER2-negative IBC at Royal Melbourne Hospital, a multi-omic test stratified patients by LRR risk and RT benefit, identifying subgroups who could safely omit RT and those with elevated risk who benefited significantly.
102 Novel Prognostic and Predictive Locoregional Biosignature for Risk Stratification of Early-Stage Hormone Receptor–Positive Breast Cancer
ByCharlotta Wadsten,Karuna Mittal,Pat W. Whitworth,Chirag Shah, MD,Frank Vicini, MD,Naamit Gerber,Melissa Krystel-Whittemore,Clayton C. Yates,Balasubramanyam Karanam,Walter Bell,Charles E. Cox, MS, FACS,Abigail Beard,Geza Acs,Steven C. Shivers,David J. Dabbs,Jess Savala,Mark Mentrikoski,Troy Bremer 104 Identification of Ductal Carcinoma In Situ Patients With Low-Risk Clinicopathology Who Benefit From Radiation Therapy With and Without Endocrine Therapy After Breast-Conserving Surgery Assessed With the 7-Gene Biosignature
ByPat W. Whitworth,Chirag Shah, MD,Frank Vicini, MD,Rachel Rabinovitch, MD,Julie A. Margenthaler, MD,Fredrik Warnberg,Micheal Leo,Sheila Weinmann,G. Bruce Mann,David J. Dabbs,Jess Savala,Steven C. Shivers,Karuna Mittal,Troy Bremer 
72 A Novel Biosignature for Early- Stage Invasive Breast Cancer to Predict Radiotherapy Benefit and Assess Recurrence Risk for Patients Treated With Breast- Conserving Surgery
ByTroy Bremer,Karuna Mittal,Chirag Shah, MD,Frank Vicini, MD,Naamit Gerber,Melissa Krystel-Whittemore,Clayton C. Yates,Balusubramanyam Karanam,Geza Acs,Elizabeth Pernicone,Melissa Tempest,Charles E. Cox, MS, FACS,Steven C. Shivers,Lotta Wadsten 
38 Comparing Risk Stratification and Radiotherapy Benefit for Patients With DCIS Using a 7-Gene Biosignature as Compared to a Clinicopathologic Nomogram
ByJulie A. Margenthaler, MD,Karuna Mittal,Frank A. Vicini, MD,Chirag Shah, MD,Rachel Rabinovitch, MD,Pat W. Whitworth,Brian Czerniecki,David J. Dabbs,G. Bruce Mann,Fredrik Wärnberg,Sheila Weinmann,Michael Leo,Steven C. Shivers,Troy Bremer 39 7-Gene Predictive Biosignature Improves Risk Stratification for Breast Ductal Carcinoma In Situ Patients Compared to Clinicopathologic Criteria, Identifying a Low-Risk Group Not Clinically Benefiting from Adjuvant Radiotherapy
ByRachel Rabinovitch, MD,Frank A. Vicini, MD,Chirag Shah, MD,Julie A. Margenthaler, MD,Brian Czerniecki,Pat W. Whitworth,David J. Dabbs,G. Bruce Mann,Fredrik Wärnberg,Sheila Weinmann,Michael Leo,Jess Savala,Steven C. Shivers,Karuna Mittal,Troy Bremer 40 Characterization of Recurrence Risk After Lumpectomy and Radiotherapy in HER2-Positive Ductal Carcinoma in Situ of the Breast Using a 7-Gene Predictive Biosignature: Implications for the NSABP-B43 Trial Results
ByFrank A. Vicini, MD,Chirag Shah, MD,Rachel Rabinovitch, MD,Pat W. Whitworth,Julie A. Margenthaler, MD,Brian Czerniecki,David J. Dabbs,Sheila Weinmann,Michael Leo,G. Bruce Mann,Fredrik Wärnberg,Jess Savala,Steven C. Shivers,Karuna Mittal,Troy Bremer 
37 The Routine Use of Bioimpedance Spectroscopy Measurements in the Clinic as a Surrogate for Bone Mineral Content in Oncology Patients: Practical Application of the SOZO Device
BySteven C. Shivers,Pat W. Whitworth,Rachel Rabinovitch, MD,Frank Vicini, MD,Chirag Shah, MD,Fredrik Wärnberg,G. Bruce Mann,Karuna Mittal,Troy Bremer 38 Clinicopathological Risk Factors, Poorly Stratified Baseline Risk, and RT Benefit Compared to DCISionRT in Patients With Ductal Carcinoma in Situ
ByPat W. Whitworth,Rachel Rabinovitch, MD,Frank A. Vicini, MD,Chirag Shah, MD,Fredrik Wärnberg,G. Bruce Mann,Steven C. Shivers,Karuna Mittal,Troy Bremer 
At this time RT following BCS remains the standard of care for most patients. Current tools, including prognostic scores and tumor genetics, have failed to identify a cohort for whom RT confers no benefit with respect to invasive recurrences.
APBI is a technique that offers women with early-stage breast cancer a choice. The preponderance of evidence supports the efficacy and safety of this technique, and it should continue to be offered to appropriately selected patients on and off protocol.
Our case illustrates the fact that MDS-associated GS can be treated palliatively with radiation and hypomethylating agents in an appropriate setting. With the growing geriatric patient population, effective treatment options are needed in this disease.
